Biotie To Present At The 3rd Annual Rodman & Renshaw Global Healthcare Conference In Monte Carlo
Webcast will be available at www.biotie.com
11.05.2006, Biotie Therapies Corp. (OMX: BTH1V), the Finnish pioneer in developing oral pharmaceutical treatments for dependence disorders, announced today that Dr. Timo Veromaa, President and Chief Executive Officer, will be presenting at the 3rd Annual Rodman & Renshaw Global Healthcare Conference in Monte Carlo, on Tuesday May 16, 2006, at 09:05 a.m. local time. A webcast of the presentation will be available on the Company’s website, www.biotie.com.
The Rodman & Renshaw Annual Global Healthcare Conference has rapidly become one of the premier events on the Life Sciences calendar, with more than 150 emerging growth biotechnology companies presenting at this year’s conference. The event will unite companies with institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities.
BioTie has a strong development pipeline which focuses on proprietary healthcare products targeting dependence disorders, inflammatory diseases and thrombosis. BioTie’s lead product for dependence disorders, the opioid receptor antagonist nalmefene, has completed two Phase III clinical trials for the treatment of alcoholism and alcohol dependence in the UK and Finland, and a phase II clinical study in the USA in patients diagnosed with pathological gambling disorder.
BioTie last month signed a marketing and distribution agreement with Britannia Pharmaceuticals Limited for nalmefene’s alcoholism indication in the UK and Ireland. Based on recent scientific advice obtained from the UK Medicines and Healthcare products Regulatory Authority (“MHRA”) BioTie, together with Britannia, intends to submit a Marketing Authorisation Application (MAA) for the product’s alcoholism indication to the MHRA by the end of the second quarter of 2006. This is a significant development for BioTie and the first step in the Company’s accelerated European strategy for nalmefene in its alcohol indication.
As well as the agreement with Britannia Pharmaceuticals, BioTie also has commercial agreements with F. Hoffmann la Roche, Somaxon Pharmaceuticals, and Seikagaku Corporation.
- Ends -
Notes to editors
Biotie Therapies Corp.
BioTie is a Finnish drug development company, with a focus on dependence disorders, inflammatory diseases and thrombosis. In particular, it is a pioneer in dependence disorders and has been developing nalmefene for the treatment of alcoholism and pathological gambling since 1999. It also has novel products in development for the treatment of inflammation and thrombosis. The Company was founded in 1996.
In addition to its plans for nalmefene in its alcohol indication, BioTie is also developing the product for the treatment of other dependence disorders. It has a licensing agreement for that indication covering North America with Somaxon Pharmaceuticals, which is conducting a Phase II/III trial amongst US patients diagnosed with pathological gambling disorder and a pilot phase II trial in nicotine addiction for smoking cessation There are 2.2 million patients in the USA alone diagnosed with pathological gambling (source: Datamonitor: Behavioural disorders 07/03).
BioTie’s shares are listed on the Helsinki Stock Exchange (Healthcare, NM-list)
For more information, please visit www.biotie.com
- Contact Information
- Charlie Jack
- UK media enquiries
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.